Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study

• Published in: Journal for immunotherapy of cancer Vol. 13; no. 5; p. e011545
• Main Authors: Quandt, Zoe, Lucas, Anastasia, Liang, Samantha I, Yang, EnJun, Stone, Samantha, Fadlullah, Muhammad Zaki Hidayatullah, Bayless, Nicholas L, Marr, Sara Siebel, Thompson, Marshall A, Padron, Lacey J, Bucktrout, Samantha, Butterfield, Lisa H, Tan, Aik Choon, Herold, Kevan C, Bluestone, Jeffrey A, Anderson, Mark S, Spencer, Christine N, Young, Arabella, Connolly, John E
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 12.05.2025; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Adult; Aged; Cancer therapies; Clinical cancer immunotherapy; Demographics; Drug-Related Side Effects and Adverse Reactions - etiology; Female; Humans; Hypothyroidism; Immune Checkpoint Inhibitors; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immune related adverse event - irAE; Immunotherapy; Male; Middle Aged; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - mortality; Oncology; Ontology; Patients; Prospective Studies; Quality control; Risk Factors; Standard of care; Statistical analysis; Steroids; Steroids - therapeutic use; Variables; Immune Checkpoint Inhibitors; Immunotherapy; Immune related adverse event - irAE
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2025-011545

BackgroundImmune checkpoint inhibitors (ICIs) have led to enduring responses in subsets of patients with cancer. However, these responses carry the risk of immune-related adverse events (irAEs), which can diminish the overall benefit of ICI treatment. While associations between irAE development and overall survival have been increasingly documented, there is a need for further understanding of these connections in large prospective real-world cohorts.MethodsThe Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets (RADIOHEAD) study, a pan-tumor, prospective cohort of 1,070 individuals undergoing standard of care first-line ICI treatment, aims to identify factors driving irAEs and clinical response. Clinical data and longitudinal blood samples were collected prospectively at multiple time points from 49 community-based oncology clinics across the USA. Structured, harmonized clinical data underwent unbiased statistical analysis to uncover predictors of real-world overall survival (rwOS) and risk factors for irAEs.ResultsAcross 1,070 participants’ treatment courses, RADIOHEAD accumulated over 4,500 clinical data points. Patients experiencing any irAE (25.4%, n=272) exhibited significantly improved rwOS in the pan-tumor cohort (n=1,028, HR=0.41, 95% CI=(0.31, 0.55)). This association persisted when adjusting for age and metastatic disease in multivariate time-dependent Cox proportional hazard analysis, and was consistent across major tumor subtypes, including lung cancer and melanoma. Skin and endocrine irAEs of any grade were strongly associated with improved rwOS (Cox proportional hazard analysis, skin, p=2.03e−05; endocrine, p=0.0006). In this real-world cohort, the irAE rate appeared lower than those reported in clinical trials. Patients receiving corticosteroids prior to initiation of ICI treatment had significantly worse survival outcomes than non-users (HR 1.37, p=0.0054), with a stronger association with systemic steroid use (HR 1.75, p=0.0022). The risk of irAE was increased by exposure to combination immunotherapy relative to monotherapy (OR 4.17, p=2.8e−7), zoster vaccine (OR 2.4, p=5.2e−05), and decreased by prior chemotherapy (OR 1.69, p=0.0005).ConclusionThe RADIOHEAD cohort is a well-powered, real-world cohort that clearly demonstrates the association between irAE development with improved response and baseline steroid use with worse response to ICI treatment after adjustment for survival bias.